lncRNA MCM3AP‑AS1 promotes the development of oral squamous cell carcinoma by inhibiting miR‑363‑5p
Affiliations: Department of Stomatology, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277100, P.R. China
- Published online on: May 12, 2020 https://doi.org/10.3892/etm.2020.8738
Copyright: © Hou
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The aim of the present study was to study the mechanism of the long non‑coding (lnc)RNA MCM3AP‑AS1 in the development of oral squamous cell carcinoma (OSCC). Patients with OSCC (n=36) volunteered to join the study, and their tumor/normal tissues were collected. MCM3AP‑AS1 and microRNA (miR)‑363‑5p expression in tissues and cells was determined by reverse transcription‑quantitative (RT‑q)PCR. Following transfection, a CCK‑8 assay and Transwell experiments were conducted to explore the effects of MCM3AP‑AS1 on OSCC cell proliferation, migration and invasion. The interaction between MCM3AP‑AS1 and miR‑363‑5p was detected by luciferase reporter gene assay. RT‑qPCR analysis demonstrated significantly higher MCM3AP‑AS1 expression in tumor tissues or OSCC cells compared with normal tissues or human oral keratinocytes cells (P<0.05). A high MCM3AP‑AS1 level was associated with poor prognosis in OSCC patients (P<0.05 or P<0.01). Compared to the small interfering (si)‑negative control (NC) group, OSCC cells of si‑MCM3AP‑AS1 group exhibited markedly lower optical density (at 450 nm) value and relative migration and invasion (P<0.05). miR‑363‑5p was directly inhibited by MCM3AP‑AS1. OSCC cells of si‑MCM3AP‑AS1 + inhibitor‑NC group exhibited clearly lower relative proliferation, migration and invasion compared with cells of si‑NC + inhibitor‑NC group and si‑MCM3AP‑AS1 + miR‑363‑5p inhibitor group (P<0.05). MCM3AP‑AS1 promoted OSCC cells proliferation, migration and invasion by inhibiting miR‑363‑5p.